Cingulate Inc banner

Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 6.82 USD -5.54% Market Closed
Market Cap: $46.1m

During the last 3 months Cingulate Inc insiders bought 166.7k USD , and have not sold any shares. The stock price has increased by 79% over this period (open performance analysis).

The last transaction was made on Feb 6, 2026 by Brams Matthew (Chief Executive Officer) , who bought 9.8k USD worth of CING shares.

Last Transactions:
Brams Matthew
Chief Executive Officer
$+9.8k
Schaffer Shane J.
Chief Executive Officer
$+34.3k
Callahan Jennifer L.
Chief Financial Officer
$+24.5k
Werth Peter J.
Chief Executive Officer
$+98.1k
Myers Laurie
$-841.3
Callahan Jennifer L.
$+14.1
Werth Peter J.
$+4.2k
Callahan Jennifer L.
$+8.1
Callahan Jennifer L.
$+18.4
Schaffer Shane J.
$+42.7
Schaffer Shane J.
$+3.9
Schaffer Shane J.
$+55.6
Callahan Jennifer L.
$+30.7
Werth Peter J.
$+118.9
Schaffer Shane J.
$+7.1
Callahan Jennifer L.
$+5.9
Callahan Jennifer L.
$+14.7
Gilgallon Craig S.
$+12.6
Myers Laurie
$+4.5
Givens Gregg Wm
$+311.7
Callahan Jennifer L.
$+22.5
Werth Peter J.
$+471.1
Myers Laurie
$+4.7
Myers Laurie
$+1.2
Myers Laurie
$+1.2
Medeiros Curtis
$-92.5
Werth Peter J.
$+202.3
Myers Laurie
$+1.4
Callahan Jennifer L.
$+11.1
Callahan Jennifer L.
$+0
Schaffer Shane J.
$+64.5
Givens Gregg Wm
$+156.3
View All Transactions

During the last 3 months Cingulate Inc insiders bought 166.7k USD , and have not sold any shares. The stock price has increased by 79% over this period (open performance analysis).

The last transaction was made on Feb 6, 2026 by Brams Matthew (Chief Executive Officer) , who bought 9.8k USD worth of CING shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
4
166.7k USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Cingulate Inc
Insider Trading Chart

Cingulate Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Cingulate Inc
Last Insider Transactions

Global
Insiders Monitor

Cingulate Inc
Glance View

Market Cap
46.1m USD
Industry
Pharmaceuticals

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

CING Intrinsic Value
4.98 USD
Overvaluation 27%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top